Highest-materiality recent filing
Daré Bioscience receives Nasdaq delisting notice for equity deficiency; plans to request hearing
Nasdaq notified Daré on July 13, 2026 that stockholders' equity was below $2.5M as of March 31, 2026.
Daré Bioscience reports Q1 2026 cash $18.5M; first product revenue expected June 2026
Cash and equivalents $18.5M as of March 31; working capital ~$0.5M; revenue $0.2M from Gates Foundation services.
Daré Bioscience FY2025: $24.7M cash, $20.8M equity proceeds; DARE to PLAY revenue expected Q2 2026
Cash and cash equivalents $24.7M at Dec 31, 2025; working capital $3.4M.
Bayer terminates Ovaprene license; Daré regains full rights, Phase 3 study continues
Bayer HealthCare terminated Ovaprene license agreement effective Feb 24, 2026 due to strategic prioritization.
DARE Bioscience reports Q3 cash $23.1M; Sildenafil Cream on track for Dec launch via 503B
Cash and equivalents $23.1M; working capital $3.8M as of Sep 30, 2025.
Cash of $5.0M at June 30; working capital deficit $12.6M; raised ~$17.6M net from ATM and $6M grant post-quarter.
Dare Bioscience raises $16.5M, believes it regains Nasdaq equity compliance
Raised approx. $16.5M gross from ATM and equity line sales since Mar 31, 2025.
Daré's Ovaprene Phase 3 interim shows ~9% pregnancy rate; DSMB OK to continue
DSMB recommended study continue without modification after planned interim safety analysis.
Nasdaq panel approves Dare Bioscience's compliance plan; deadline Aug 12, 2025
Panel approved modified plan to regain compliance with Nasdaq Listing Rules 5550(b)(1) (≥$2.5M equity) or 5550(b)(2) (≥$35M MVLS).
Daré Bioscience Q1 2025: Cash $10.3M, R&D down 31%, expects first revenue in Q4 2025
Cash and equivalents $10.3M at March 31, 2025; working capital deficit of $9.4M.
Nasdaq grants Daré extension until Aug 12, 2025 to regain listing compliance
Extension conditional on meeting stockholders' equity >$2.5M by April 30, 2025 and further increase by July 15, 2025.
Dare Bioscience reports FY2024 cash $15.7M, plans Sildenafil Cream 503B launch in Q4 2025
Cash and equivalents $15.7M at Dec 31, 2024; working capital deficit of $3.2M.
Dare Bioscience receives Nasdaq delisting notice for failing to meet $35M minimum MVLS rule
On Feb 13, 2025, Nasdaq notified Dare Bioscience that its common stock is subject to delisting for failure to regain compliance with the Minimum MVLS Rule by Feb 10, 2025.
Daré announces Phase 3 plans for Sildenafil Cream for FSAD; protocol submission in Q1 2025
Will submit Phase 3 protocol and statistical plan to FDA in Q1 2025; target mid-2025 to start the study.
Daré Bioscience Q3 2024: cash $11.2M; grants up to $10.7M and $10M; pipeline advancing
Cash and equivalents $11.2M at Sept 30, 2024; R&D expenses fell 60% YoY to $2.7M; G&A $2.0M.
Daré Bioscience awarded $10M from ARPA-H to develop HPV treatment candidate DARE-HPV
Award of $10M from ARPA-H Sprint for Women's Health; milestone-based payments over 24 months.
Daré Bioscience secures $15M common stock purchase facility with Lincoln Park Capital
Entered $15M common stock purchase agreement with Lincoln Park Capital Fund, LLC.
Dare Bioscience Q2 cash $16.4M; Ovaprene Phase 3 enrolling; Sildenafil Cream awaits FDA feedback
Cash and equivalents $16.4M at June 30, 2024; received $22M non-dilutive royalty financing from XOMA in April 2024.
Daré regains Nasdaq minimum bid price compliance, delisting risk removed
Nasdaq notified Daré that closing bid price was ≥$1.00 for 10 consecutive sessions; compliance achieved.
1-for-12 reverse stock split effective July 1, 2024; shares reduce from ~101.1M to ~8.4M.
Re-elected directors Jessica D. Grossman, M.D. (28,626,331 for) and Susan L. Kelley, M.D. (28,623,481 for) as Class I directors.
Daré Bioscience Q1 cash $3.6M, secures $22M royalty financing; Ovaprene Phase 3 ongoing
Cash & equivalents $3.6M at March 31, 2024; subsequent $22M non-dilutive royalty financing from XOMA and $1M grant installment.
XOMA paid $22M upfront for 100% of Daré's net XACIATO royalties and milestones (after deductions); Daré also sold minority interest in Ovaprene/Sildenafil future revenue.
Net loss of $30.1M for FY2023; revenue of $2.8M from XACIATO milestone payments.
Dare Bioscience receives Nasdaq delisting notice for bid price below $1.00 per share
Received Nasdaq delisting notice on Jan 17, 2024 for failing to meet minimum $1.00 bid price requirement.
Dare Bioscience secures up to $12M royalty-backed financing; $5M upfront, warrants issued
Sold right to receive future royalty payments on XACIATO to United in Endeavour, LLC for up to $12M; $5M received at closing.
Dare Bioscience reports positive Phase 1 topline results for DARE-PDM1 in primary dysmenorrhea
DARE-PDM1 (vaginal diclofenac hydrogel) was well-tolerated; no serious AEs; 85% of AEs mild.
On January 24, 2024, John Fair, our Chief Commercial Officer, informed us that, in light of the full-scale commercial launch of XACIATO TM —bringing to fruition one of his primary responsibilities as Chief Commercial Officer—he will be resigning from all positions with us and his employment with us will end effective June 30, 2024.
Ms. Haring-Layton, our current Vice President, Accounting & Finance, was appointed as our Chief Accounting Officer and will serve as our principal accounting officer.
On January 23, 2024, Lisa Walters-Hoffert informed Daré Bioscience, Inc. (“our,” “we”, “us,” “our,” or the “Company”) that she will retire from all positions with the Company, and her employment with the Company will end, effective January 26, 2024.
Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer
Max materiality 0.80 · Median 0.60 · Most common event other_material